In this trial, 128 patients with HER2-positive breast cancer received six cycles of chemotherapy every three weeks (three cycles of docetaxel 100 mg/m2 followed by three cycles of fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2). Here, ERBB2 is linked to breast cancer.